Resistance to nonnucleoside inhibitors of HIV-I reverse transcriptase

Drug Resistance Updates

Volumn 2, Issue 1, 1999, Pages 56-67

  Bacheler, Lee T ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; LAMIVUDINE; LOVIRIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ALLOSTERISM; AMINO ACID SUBSTITUTION; CLINICAL TRIAL; CROSS RESISTANCE; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; VIRUS MUTATION;

EID: 0033081564     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1998.0064     Document Type: Article

References (100)

1. Pauwels R., Andries K., Desmyter J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 343:1990;470-474.
2. Merluzzi V. J., Hargrave K. D., Labadia M. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 250:1990;1411-1413.
3. Saari W. S., Hoffman J. M., Wai J. S. 2-pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors. J Med Chem. 34:1991;2922-2925.
4. Balzarini J., Perez-Perez M. J., San-Felix A. [2′,5′-Bis-O-(tert-butyldimethylsilyl)]- 3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 36:1992;1073-1080.
5. Romero D. L., Busso M., Tan C. K. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA. 88:1991;8806-8810.
6. Montaner J. S., Reiss P., Cooper D. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 279:1998;12, 930-937.
7. Ruiz, N. A double-blind pilot study to evaluate the antiretroviral activity, tolerability of DMP 266 in combination with indinavir (cohort III).
8. Staszewski, S. Morales-Ramirez, J. Flanigan, T. A phase II, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) +lamivudine (3TC) versus IDV + ZDV + 3TC at 24 weeks [Abstract 22336], 1998.
9. Green, S. Para, M. F. Daly, P. W. Interim analysis of plasma viral burden reductions and CD4+ increases in HIV-1 infected patients with Rescriptor (DLV)+Retrovir (ZDV)+Epivir (3TC) [Abstract 12219], 1998.
10. Wu J. C., Warren T. C., Adams J. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry. 30:1991;2022-2026.
11. Cohen K. A., Hopkins J., Ingraham R. H. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem. 266:1991;14670-14674.
12. Ding J., Das K., Tantilla C., Zhang W. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8A resolution. Structure. 3:1995;365-379.
13. Smerdon S. J., Jaeger J., Wang J. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc.Nat.Acad.Sci.USA. 91:1994;3911-3915.
14. Sayle R. H., Milner-White E. J. RASMOL: biomolecular graphics for all. Trends in Biochem Sci. 20:1995;374-376.
15. Boyer P. L., Ding J., Arnold E., Hughes S. H. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents and Chemother. 38:1994;1909-1914.
16. Jonckheere H., Taymans J. M. Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′, 2′′-dioxide)] (TSAO) derivatives is determined by the mutation Glu 138->Lys on the p51 subunit. J Biol Chem. 269:1994;25255-25258.
17. Esnouf R. M., Ren J., Hopkins A. L. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci USA. 94:1997;3984-3989.
18. Hsiou Y., Ding J., Das K., Clark A. D. Jr, Hughes S. H., Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure. 4:1996;853-860.
19. Hsiou, Y. Das, K. Ding, J. Crystal structures of wild-type and mutant HIV-1 reverse transcriptase and non nucleoside inhibitors: implications for drug resistance mechanisms.
20. Das K., Ding J., Hsiou Y. Crystal structures of 8-Cl and 9-C1 TIBO complexed with wild-type HIV-1 RT and 8-C1 TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol. 264:1996;1085-1100.
21. Boyer P. I., Gao H-Q., Hughes S. H. A mutation at position 190 of human innumodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicorb. Agents and Chemother. 42:1998;447-452.
22. Pelemans H., Esnouf R. M., Parniak M. A., Vandamme A. M., De Clercq E., Balzarini J. A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. J Gen Virol. 79:1997;1347-1352.
23. Maga G., Amacker M., Ruel N., Hubscher U., Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 274:1997;738-747.
24. Bacolla A., Shih C. K., Rose J. M. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. J Biol Chem. 268:1993;22,16571-16577.
25. Quinones-Mateu M. E., Soriano V., Domingo E., Menendez-Arias L. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology. 236:1997;364-373.
26. Descamps D., Collin G., Loussert-Ajaka I., Saragosti S., Simon F., Brun-Vezinet F. HIV-1 group O sensitivity to antiretroviral drugs. AIDS. 9:1995;977-978.
27. Descamps D., Collin G., Letourneur F. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol. 71:1997;8893-8898.
28. Proc Natl Acad. SCA U S A. 88:1991;9878-9882.
29. Condra J. H., Emini E. A., Gotlib L. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob. Agents and Chemother. 36:1992;1441-1446.
30. Isaka Y., Sato A., Kawauchi S. Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor. Microbiol Immunol. 42:1997;3, 195-202.
31. Deschamps, D. Apetrei, C. Collin, G. Damond, F. Simon, F. Brun-Vezinet, F. In vitro drug susceptibility and sequence analysis of HIV-1 group M isolates belonging to different subtypes.
32. Richman D., Shih C. K., Lowy I. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A. 88:1991;11241-11245.
33. Mellors J. W., Dutschman G. E., Im G. J., Tramontano E., Winkler S. R., Cheng Y. C. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol. 41:1992;446-451.
34. Wei X. Viral dynamics in human immunodeficienty virus type 1 infection. Nature. 373:1995;117-122.
35. Nature. 373:1995;123-126.
36. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
37. Mansky L. M., Temin H. M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than thatpredicted from the fidelity of purified reverse transcriptase. J Virol. 69:1995;5087-5094.
38. Coffin J. M. HIV Populations dynamics in vivo: impliciations for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
39. Larder B. A., Kohli A., Bloor S. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′, 3′- dideoxyinosine or AZT plus 2′, 3′-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol. 70:1996;5922-5929.
40. Havlir D. V., Eastman C., Gamst A., Richman D. D. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 70:1996;7894-7899.
41. Kleim J. P., Winkler I., Rosner M. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology. 231:1997;112-118.
42. Antiviral Research. 33:1997;109-115.
43. Keulen W., Boucher C., Berkhout B. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Research. 31:1996;45-57.
44. Richman D. D., Havlir D., Corbeil J., Looney D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 68:1994;1660-1666.
45. 3: AIDS Clinical Trials Group Protocol 208. J Infect Dis. 172:1995;1379-1383.
46. Cheeseman S. H., Havlir D., McLaughlin M. M. Phase I/II evalutation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J AIDS and Hum Retrovirol. 8:1995;141-151.
47. Havlir D., Cheeseman S. H., Mclaughlin M. High-dose nevirpaine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J of Infect D. 171:1995;537-545.
48. Carr A., Vella S., de Jong M. D. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-1 infected patients. The Dutch-Italian, Australian Nevirapine Study Group., AIDS. 10:1996;635-641.
49. Dueweke T. J., Pushkarskaya T., Poppe S. M. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 90:1993;4713-4717.
50. Fan N., Rank K. B., Evans D. B., Thomas R. C., Tarpley W. G., Sharma S. K. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. FEBS Lett. 370:1995;59-62.
51. Wathen, L. K. Freimuth, W. W. Batts, D. H. Cox, S. R. Phenotypic and genotypic characterization of HIV-1 isolates from patients treated with combined AZT and delavirdine mesylate (DLV) therapy, 3rd International Workshop on HIV Drug Resistance, Kauai, HI, 1995:42.
52. Freimuth W. W. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Med Biol. 394:1996;279-289.
53. Demeter L., Shafer R., Para M. Delavirdine susceptivility of HIV-1 isolates obtained from patients receiving delavirdine monotherapy. 1996.
54. Salzman, NK, Lanne, H. C. Chappey, C. Patterns of HIV drug resistance during combined or monotherapy with delavirdine.
55. Been-Taktak A. M. M., Joly V., Sitbon G. Combination therapy with delavirdine mesylate (DLV) and AZT: virology data from an European Phase II trial. J Acquir Immune Defic Syndr Hum Retroviruses. 10:1995;s23-24.
56. Demeter L. M., Meehan P. M., Morse G. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol. 14:1997;136-144.
57. Winslow D. L., Garber S., Reid C. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS. 10:1996;1205-1209.
58. Bacheler L. T., George H., Abremski K., Emini E., Schleif W. A., Condra J. H. Mutations associated with viral load rebound in patients treated with the HIV-1 non- nucleoside reverse transcriptase inhibitor DMP266 in combination with the HIV-1 Protease inhibitor crixivan. 1997;ICAAC, Toronto.
59. Bacheler, L. George, H. Hollis, G. Resistance to efavirenz (Sustiva) in vivo. 5th Conference on Retroviruses and Opportunistic Infections, 1998.
60. Bacheler, L. T. Anton, E. Jeffrey, S. RT gene mutations associated with resistance to efavirenz.
61. Katzenstein, D. A. Shafer, R. W. Bosch, R. J. Albrecht, M. Hammer, S. M. Reverse transcriptase and protease genotypes of nucleoside-experienced subjects with virological failure on nelfinavir or efavirnez.
62. Seki M., Sadakata Y., Yuasa S., Baba M. Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442. Antiviral Chem. and Chemother. 6:1995;73-79.
63. Harris J., Borroto-Esoda K., Moxham C., Rousseau F., McCreedy B. Development of genotypic and phenotypic resistance to MKC-442, a potent and selective inhibitor of HIV-1 replication. Antiviral Res. 37:1998.
64. Schmit J. C., Cogniaux J., Hermans P. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis. 174:1996;962-968.
65. Staszewski S., Miller V., Rehmet S. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS. 10:1996;F1-7.
66. Jeffrey, S. Baker, D. Tritch, R. Rizzo, C. Bacheler, L. A resistance and cross resistance profile for Sustiva® (efavirenz, DMP 266), 1998.
67. Moeremans, M. Raeymaeker, M. Van den Broeck, R. Stoffels, P. Andries, K. Genotypic analysis of HIV-1 isolates from patients receiving loviride alone, or in combination with mucleoside reverse transcrptase inhibitos.
68. Miller V., Staszewski S., Boucher C. A. B., Phair J. P. Clinical experience with non-nucleoside reverse transcriptase inhibitors. AIDS. 11(supplA):1997;S157-164.
69. Nunberg J. H., Schleif W. A., Boots E. J. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 65:1991;4887-4892.
70. Saag M. S., Emini E. A., Laskin O. L. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 329:1993;1065-1072.
71. Schooley R. T., Campbell T. B., Kuritzkes D. R. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 12:1996;363-370.
72. Staszewski S., Massari F. E., Kober A. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis. 171:1995;1159-1165.
73. Balzarini J., Pelemans H., Aquaro S. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol. 50:1996;394-401.
74. Buckheit R. W. Jr, Hollingshead M., Stinson S. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res Hum Retroviruses. 13:1997;789-796.
75. Balzarini J., Pelemans H., Esnouf R., De Clercq E. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res Hum Retroviruses. 14:1998;255-260.
76. Olmsted, R. A. Slade, D. E. Kopta, L. A. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes, J Virol, 1996, 70, 3698-3705.
77. Balzarini J., Karlsson A., Vandamme A. M. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′, 5′-bis-O-(tert- butyldimethylsilyl)-3′-spiro- 5′′-(4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide)]-beta-D- pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc Natl Acad Sci USA. 90:1993;6952-6956.
78. Fujiwara T., Sato A., M E. I. M. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42:1998;1340-1345.
79. Young S. D., Britcher S. F., Tran O. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 39:1995;2602-2605.
80. Pelemans H., Esnouf R., Dunkler A. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J Virol. 71:1997;8195-8203.
81. Kleim J. P., Winkler I., Rosner M. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology. 231:1997;112-118.
82. Antimicrob Agents Chemother. 36:1992;2664-2669.
83. Byrnes V. W., Emini E. A., Schleif W. A. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to revese transcriptase inhibitors. Antimicrob Agents Chemother. 38:1994;1404-1407.
84. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 90:1993;5653-5656.
85. Boucher C. A., Cammack N., Schipper P. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 37:1993;2231-2234.
86. Larder B. A., Kemp S. D., Harrigan P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 269:1995;5224,696-699.
87. Rezende L. F., Drosopoulos W. C., Prasad V. R. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res. 26:1998;12,3066-3072.
88. Hsu M., Inouye P., Rezende L. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res. 25:1997;4532-4536.
89. Hamburgh M. E., Drosopoulos W. C., Prasad V. R. The influence of 3TC-resistance mutations E89G and M184V in the human immunodeficiency virus reverse transcriptase on mispair extension efficiency. Nucl. Acids Res. 26:1998;4389-4394.
90. Wainberg M. A., Drosopoulos W. C., Salomon H. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 271:1996;1282-1285.
91. Wainberg M. A. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. Leukemia. 11:1997;85-88.
92. Drosopoulos W. C., Prasad V. R. Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro. J Virol. 72:1998;4224-4230.
93. Jonckheere H., Witvrouw M., De Clercq E. Lamivudine resistance of hiv type 1 does not delay development of resistance to nonnucleoside hiv type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1. AIDS Res Hum Retroviruses. 14:1998;249-253.
94. Balzarini J and Kleim J-P. Drug resistance development of HIV-1 upon combination therapy with 3TC And NNRTIS. International Antiviral News. 5:1997;6-8.
95. Schuurman R., Nijhuis M., van Leeuwen R. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 171:1995;1411-1419.
96. Balzarini J., Pelemans H., Karlsson A., De Clerc Q. E., Kleim J. P. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci USA. 93:1996;13152-13157.
97. Kleim J. P., Bender R., Kirsch R. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 39:1995;2253-2257.
98. Kleim J. P., Rosner M., Winkler I. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor specific (RT LEU-74VAL or ILE and VAL-75LEU or ILE) HIV-1 mutants. Proc. Natl. Acad. Sci. USA. 93:1996;34-38.
99. Havlir D., Cheeseman S. H., McLaughlin M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 171:1995;537-545.
100. de Jong M. D., Vella S., Carr A. High-dose nevirapine in previously untreated human immunodificienty virus type 1-infected persons does not result in sustained suppression of viral replication. J of Infect Diseases. 175:1997;966-970.